Korro Bio Q2 FY26 net loss narrows to USD 18.92 million; revenue posts no collaboration revenue
KRRO•Q2 FY26 results
- Korro posted a net loss of USD 18.9 million, narrowing from USD 25.8 million a year earlier; loss per share improved to USD 1.07 from USD 2.74.
- Research and development expense fell to USD 13.6 million from USD 20.1 million; general and administrative costs eased to USD 6.5 million from USD 7.3 million.
- Revenue was no revenue versus USD 1.5 million, reflecting a 12-month pause of its Novo Nordisk collaboration agreed in November 2025.
- Cash, cash equivalents and marketable securities rose to USD 137.9 million from USD 85.2 million at Dec. 31, 2025, extending runway into the second half of 2028.
- KRRO-121 remains on track for a first-in-human trial in the second half of 2026; KRRO-111 was named a development candidate for Alpha-1 Antitrypsin Deficiency.
Related News
The New York Times Company <NYT.N>: BofA Global Research cuts price objective to $75.00 from $80.00
NYT•
Ingles Markets FY26 Q3 net income slips 1.1% to $25.9 million; net sales rise 1.5% to $1.37 billion
IMKTA•
